CAS NO: | 41575-94-4 |
包装 | 价格(元) |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
1 g | 电议 |
5 g | 电议 |
生物活性 | Carboplatin (NSC 241240) is aDNA synthesisinhibitor which binds to DNA, inhibits replication and transcription and induces cell death. Carboplatin (NSC 241240) is a derivative of CDDP and a potent anti-cancer agent. | ||||||||||||||||
IC50& Target | DNA Alkylator[1] | ||||||||||||||||
体外研究 (In Vitro) | Carboplatin is an antitumor agent, with an increased DNA-binding activity in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts[1]. Carboplatin is less cytotoxic to human ovarian cells such as A2780, SKOV3, IGROV1 and HX62 than 17-AAG, with IC50s of 6.177, 12.442, 2.233 and 116.068 μM, respectively. Moreover, Carboplatin does not affect HSP90 or change the activity of 17-AAG to inhibit HSP90[2]. Carboplatin reduces the viability of Brca1 (IC50, 3.4 μM) and Brca2 cells (IC50, 1.9 μM). Carboplatin (25 μM) combined with ABT-888 also shows an apoptotic effect in BRCA1 cells[3]. | ||||||||||||||||
体内研究 (In Vivo) | Carboplatin (60 mg/kg, i.p.) shows a modest effect on the tumor, but significantly inhibits tumor growth in combination with 17-AAG in mice bearing A2780 human ovarian cancer xenografts[2]. Carboplatin (25 mg/kg, p.o.) combined with ABT-888 delays tumor growth in Brca2 xenografts[3]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 371.25 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C6H12N2O4Pt | ||||||||||||||||
CAS 号 | 41575-94-4 | ||||||||||||||||
中文名称 | 卡铂;碳铂 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : 10.42 mg/mL(28.07 mM;ultrasonic and warming and heat to 60℃;DMSO can inactivate Carboplatin's activity) DMF : 1 mg/mL(2.69 mM;Need ultrasonic;DMSO can inactivate Carboplatin's activity) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
*以上所有助溶剂都可在本网站选购。 |